Comparative Pharmacology
Head-to-head clinical analysis: MEVACOR versus OMTRYG.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MEVACOR versus OMTRYG.
MEVACOR vs OMTRYG
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Competitive inhibitor of HMG-CoA reductase, the rate-limiting enzyme in cholesterol biosynthesis. Reduces hepatic cholesterol synthesis, leading to increased LDL receptor expression and enhanced clearance of LDL from plasma.
OMTRYG is a combination of ombitasvir, paritaprevir, and ritonavir. Ombitasvir is an NS5A inhibitor that blocks viral RNA replication and assembly. Paritaprevir is an NS3/4A protease inhibitor that prevents viral polyprotein cleavage. Ritonavir is a CYP3A4 inhibitor used to boost paritaprevir levels.
10-80 mg orally once daily in the evening.
2 mg orally twice daily; if taste disturbance occurs, reduce to 1 mg twice daily.
None Documented
None Documented
The terminal elimination half-life of lovastatin is approximately 1-2 hours for the parent drug. However, the active metabolite (lovastatin acid) has a half-life of about 1.7-2.6 hours. Despite the short half-life, the duration of HMG-CoA reductase inhibition is prolonged due to enterohepatic recirculation and tissue distribution. Once-daily dosing is effective for LDL-C reduction.
Terminal elimination half-life is 12-14 hours in healthy adults, allowing once-daily dosing. In renal impairment (CrCl <30 mL/min), half-life prolongs to 24-36 hours requiring dose adjustment.
Lovastatin is primarily excreted via the biliary/fecal route (approximately 80-85% of the absorbed dose) as metabolites. Renal excretion accounts for about 10% of the administered dose, mostly as metabolites; less than 5% is excreted unchanged in urine.
Primarily renal excretion unchanged (approximately 70%), with 30% metabolized hepatically and excreted in feces via bile. Renal clearance accounts for ~60% of total clearance.
Category C
Category C
HMG-CoA Reductase Inhibitor (Statin)
HMG-CoA Reductase Inhibitor (Statin)